Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab versus continued mepolizumab or benralizumab in severe eosinophilic asthma
2020-003612-28Phase 3Active
- Sponsor
- GSK
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of depemokimab in eosinophilic asthma (EA) and asthma (2 arms), sponsored by GSK. Primary endpoint: Annualised rate of clinically significant exacerbations over 52 weeks. Started Feb 2021; status: active.
02
Drugs
depemokimab
03
Conditions
eosinophilic asthma (EA)asthma
Beyond the preview
Go deeper on 2020-003612-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003612-28.